More setbacks for Bydureon (exenatide)
October 29, 2010 In Part 2 of the Weekly Summary show, Jay Skyler, MD, leads the discussion about the surprise setbacks to approval for the diabetes drug Bydureon (long-acting exenatide) to be marketed...
View ArticleWilliam Abraham, MD: The CardioMEMS’ heart failure pressure measurement system
October 29, 2011 By Steven Greer, MD The CardioMEMS’ heart failure pressure measurement system will be evaluated by an FDA advisory committee next month. The CHAMPION trial, led by Dr. Abraham at Ohio...
View ArticleThe risk of diabetes associated with statin drugs
http://www.youtube.com/watch?v=Q4lK3ziXbWo Produced and interviewed by Steven Greer, MD The statin drug Crestor, made by AstraZeneca, recently received an expanded label indication from the FDA to...
View ArticleMatthews Chacko, MD: Renal denervation to treat HTN
http://www.youtube.com/watch?v=POqhP7dK99g December 29, 2010 Many medical devices cause a far greater clinical impact than pharmaceutical therapies such as statins and chemotherapies. For example, ICDs...
View ArticleGordon Guyatt, MD: Update on the problem of clinical trials being stopped...
Gordon Guyatt, MD, epidemiologist, internist, and biostatistician at McMaster University updates us on the progress being made against the problem of clinical trials being stopped early to inflate...
View ArticleLon Schneider, MD: New criteria to diagnose Alzheimer’s Disease
Lon Schneider, MD, Director of USC’s Alzheimer’s Center, discusses the new lexicon to discuss prodromal Alzheimer’s and the new biomarkers to diagnose AD decades sooner than current methods. These new...
View ArticleLimitations of The Lancet papers espousing the cancer risk reduction of daily...
March 21, 2012 By Dr. Kausik Ray from St. George’s University in London Here are my thoughts on The recent Lancet papers that uses meta-analysis to study whether daily aspiring reduces the risk of...
View ArticlePaul Richardson, MD: Three-drug regimen for multiple myeloma
Dr. Paul Richardson of Harvard’s Dana-Farber Cancer Institute reviews the recent Lancet article by Cavo, et al, that was the first randomized controlled trial to compare three-drug regimen (bortezomib...
View ArticlePaul Richardson, MD: Current Therapies for Multiple Myeloma
Interviewed by Steven Greer, MD Dr. Paul Richardson, Clinical Director of the Multiple Myeloma Center at Harvard’s Dana-Farber Cancer Institute gives an overview of the current standard of care for...
View ArticleSerelaxin to treat acute heart failure
The FDA granted Novartis the coveted “Breakthrough” status for drug serelaxin to treat acute heart failure. If approved, it will be the first drug in decades to address AHF. Also, early data suggest...
View Article
